Leem (les Entreprises Du Medicament)

PARIS, September 9, 2010 - Is France an attractive investment option for the international managers of pharmaceutical companies? On what basis? What concrete measures will enable France to reindustrialise and remain a major country in pharmaceuticals over the next ten years? To provide objective answers to these questions, particularly in the framework of the CSIS (Strategic Council for Healthcare Industries), in 2009 the French Pharmaceutical Companies Association (Leem) commissioned AEC Partners to conduct a study, the first in France, amongst major pharmaceutical groups.